Pharmacia & Upjohn Discussing Mirapex Sudden Sleep Onset With FDA
Executive Summary
FDA and Pharmacia & Upjohn are discussing possible labeling changes to the Parkinson's therapy Mirapex (pramipexole) to reflect reports of sudden sleep onset in patients.
You may also be interested in...
EU Drug Advertising, E-Commerce Working Groups To Be Formed By 2000
The European Commission's Pharmaceutical Committee plans to establish ad hoc working groups on advertising and electronic commerce by late 1999 or early 2000.
EU Drug Advertising, E-Commerce Working Groups To Be Formed By 2000
The European Commission's Pharmaceutical Committee plans to establish ad hoc working groups on advertising and electronic commerce by late 1999 or early 2000.
P&U "Dear Doctor" Letter Notes New Label Warning For Sleep Onset
Pharmacia & Upjohn plans to conduct studies of Mirapex (pramipexole) in response to an increasing number of reports of sudden sleep onset during daily activities, the company said.